Precision Treatment in ACS-Role of Assessing Fibrinolysis

Despite advancements in pharmacotherapy and interventional strategies, patients with acute coronary syndrome (ACS) remain at risk of recurrent thrombotic events. In addition to an enhanced tendency to thrombus formation, impairment in the ability to naturally dissolve or lyse a developing thrombus, namely impaired endogenous fibrinolysis, is responsible for a major part of this residual risk regardless of optimal antiplatelet medication. Global assessment of endogenous fibrinolysis, including a point-of-care assay, can identify patients with ACS at persistent high cardiovascular risk and might play an important role in allowing the personalisation of potent antithrombotic therapy to enhance fibrinolytic status, providing precision treatment of ACS to improve long-term outcome.

Automated summary

Despite advancements in treatment, ACS patients still face the risk of recurrent thrombotic events, with impaired endogenous fibrinolysis playing a major role. Global assessment and personalized antithrombotic therapy based on fibrinolytic status may improve long-term outcomes in ACS.